HB
CRSP icon

Homrich & Berg’s CRISPR Therapeutics CRSP Stock Holding History

Homrich & Berg’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,750
Closed -$283K – 484
2021
Q2 		$283K Hold
1,750
– – 0.01% 380
2021
Q1 		$213K Hold
1,750
– – 0.01% 395
2020
Q4 		$268K Buy
+1,750
New +$207K 0.01% 338

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Homrich & Berg's CRSP Position: Q3 2021 in Review

Homrich & Berg sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,750 shares — an estimated $283K sold.

Homrich & Berg first reported a position in CRSP in Q4 2020 and held it in 3 quarters. The position peaked at $283K in Q2 2021. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Homrich & Berg reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Homrich & Berg sold 1,750 CRISPR Therapeutics shares in Q3 2021, an estimated $283K.
  • Homrich & Berg first reported a position in CRISPR Therapeutics in Q4 2020 and held it in 3 quarters.
  • Homrich & Berg's CRISPR Therapeutics position peaked at $283K in Q2 2021.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Homrich & Berg's 13F filing for Q3 2021, filed 8 Dec 2021.